Miguel Angel
Canales Albendea
Consultor Médico
University of Western Australia
Perth, AustraliaPublicaciones en colaboración con investigadores/as de University of Western Australia (1)
2022
-
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
The Lancet Oncology, Vol. 23, Núm. 8, pp. 1055-1065